Doctor of Philosophy / Biochemistry / Michael R. Kanost / Insect innate immune responses include prophenoloxidase activation and antimicrobial peptide production. These responses involve extracellular serine proteinase cascades that are regulated by serpins. This work involved the study of serine proteinase 16 (HP16) and serpin-3 from hemolymph of the tobacco hornworm, Manduca sexta. HP16 has an amino-terminal domain with no similarity to any characterized protein and a carboxyl-terminal S1 family serine proteinase domain. HP16 levels in plasma were highest during the wandering, prepupal, and pupal stages. HP16 mRNA levels in fat body were highest at the wandering stage. Injection of bacteria into fifth instar larvae stimulated HP16 expression. To further characterize and investigate the biological function of HP16, recombinant proteins for proHP16, two HP16 mutants, the amino-terminal domain (NT16), and three NT16 mutants were purified. Recombinant HP16 was cleaved at the predicted activation site during expression, and its amino-terminal and catalytic domains remained connected by a disulfide bond. ProHP16 in plasma was apparently activated in the presence of the microbial elicitor, zymosan. Recombinant HP16 formed a complex with serpin-1Z, indicating that it was catalytically active, but no other natural or artificial substrates were identified. Analysis of NT16 and NT16 mutants led to the discovery that multiple disulfide bond arrangements were formed in the recombinant amino-terminal domain of HP16. This work furthered the understanding of HP16 and laid a foundation for subsequent experiments involving the proteolytic activity, regulation, and biological function of HP16. Active serine proteinases in insect hemolymph are often regulated by serpins. Immunoaffinity chromatography was used to identify plasma proteinases that are inhibited by serpin-3. Four serpin-3-proteinase complexes purified from plasma were identified by immunoblot analysis as serpin-3 complexes with HP8, PAP-1, PAP-2, and PAP-3. MALDI-TOF/TOF or ESI-MS/MS analysis after separation by 1D- or 2D-PAGE confirmed serpin-3 complex formation with HP8, PAP-1, and PAP-3. ProHP8 in plasma was activated by exposure to the β-1,3-glucan curdlan and inhibited by serpin-3. Purified recombinant serpin-3 and active HP8-Xa formed an SDS-stable complex in vitro. Identification of serpin-3-proteinase complexes in plasma provides insight into proteinase targets of serpin-3 and extends the understanding of serpin/proteinase function in the immune response of M. sexta.

Im ersten Teil dieser Arbeit wurden Antikörper-bindende Epitope von humaner Proteinase 3 (hPR3), dem Autoantigen der Wegenerschen Granulomatose (WG), charakterisiert. WG ist eine Autoimmunerkrankung, die durch chronische Entzündung des oberen und unteren respiratorischen Trakts, Vaskulitis und Glomerulonephritis gekennzeichnet ist. WG ist mit Anti-Neutrophilen zytoplasmatischen- Antikörpern (ANCA) assoziiert, die spezifisch gegen konformationelle Epitope auf der Oberfläche der Serinprotease hPR3 aus azurophilen Granula neutrophiler Granulozyten gerichtet sind. Die Charakterisierung von ANCA-bindenden Epitopen ist für ein besseres Krankheitsverständis Unverzichtbar. Im Rahmen der vorliegenden Arbeit wurde nach einem geeigneten PR3-Homolog gesucht, welches sich durch den gezielten Austausch von Oberflächen- Loops für die Kartierung von ANCA-Epitopen eignet. Zunächst wurde die PR3 Aminosäuresequenz der Primaten Pan troglodytes versus (Schimpanse), Macacca mulatta (Makakke) und Hylobates pileatus (Gibbon) analysiert und die Reaktivität gegenüber ANCA mit dem humanen Homolog verglichen. Sowohl Aminosäuresequenz als auch ANCA-Kreuzreaktivität korrelierten mit der phylogenetischen Distanz zu hPR3. Aufgrund der Bindungseigenschaften von Gibbon-PR3 (gibPR3) wurde dieses Homolog für Epitopstudien herangezogen, da die Aminosäuresequenz nur geringfügig von hPR3 abweicht und die Bindung von monoklonalen Anti-hPR3-Antikörpern und WG-Patientenseren im Immunoblot ein deutlich abgeschwächtes Signal lieferte oder keine Reaktivität mehr aufwies. Für die Epitop-Charakterisierung wurden drei hPR3/gibPR3-Mutanten generiert. Die rekombinante Expression von proPR3 erfolgte in Flp-in HEK 293 Zellen und wurde von dort aus dem Zellkultur-Überstand gereinigt und mittels Enterokinase konvertiert. Um das Epitopspektrum genau zu analysieren, wurde ein ELISA entwickelt, bei dem PR3 über den C-terminal gelegenen His6-Tag an Nickel-beschichtete Mikrotiterplatten gebunden wurde. Für den monoklonalen Anti-hPR3-Antikörper MCPR3-2 konnte die Region auf die Aminosäuren Arg60, Gln63A und Leu90 (Chymotrypsinogen-Nummerierung), das für 12.8 auf Met35, Asn38A, Pro38B und Arg74 der N-terminalen PR3-Domäne eingegrenzt werden. Letztere wurde von der Mehrheit der getesteten ANCA der WG-Patienten erkannt und zeigt somit, dass es sich hierbei um ein krankheitsrelevantes Epitop handelt. Diese Region schließt dabei auch den Bindungsbereich von α1-PI ein. Im weiteren konnte gezeigt werden, dass eine Bindung des Antikörpers bei gleichzeitiger Anwesenheit von α1-PI stark von dessen Konzentration abhängig ist. Bereits bei einer α1-PI-Konzentration von 1 mg/ml, konnte eine partielle Antikörperbindung beobachtet werden. Sinkt die Konzentration deutlich, so besitzen Anti-hPR3-Antikörper die Möglichkeit an diese zu binden. Somit konkurrieren Antikörper und Inhibitor um die PR3-Bindungsstellen. Ein ausgewogenes Protease-Inhibitor-Gleichgewicht ist allerdings für eine kontrollierte Protease-Aktivität notwendig. Ist dieses gestört, so kann es zur Bindung von ANCA an hPR3 auf der Membran von Neutrophilen und deren Aktivierung kommen. Dies hat zur Folge, dass vermehrt proteolytische Enzyme freigesetzt werden, welche durch unkontrollierte enzymatische Aktivität Entzündungsreaktionen und Gewebeschädigung hervorrufen. Der zweite Teil dieser Arbeit beschäftigte sich mit der Charakterisierung einer autosomal-dominant vererbten myofibrillären Myopathie (MFM) in Kombination mit familiärer arrhythmogener rechtsventrikulärer Kardiomyopathie 7 (ARVD7) einer schwedischen Familie. Durch genomweite Kartierung mittels SNP (single nucleotide polymorphism)-Typisierung (Affymetrix Human Mapping 10K Array) wurde der Locus auf 10q22.3 bestätigt. Die Region wurde anschließend bis auf 4.1 Mbp zwischen den Markern D10S1645 und D10S1786 eingegrenzt. In diesem Intervall befinden sich 18 Kandidatengene. Nachdem die Protein-kodierenden Exons aller Gene im Krankheitsintervall sequenziert und dennoch keine signifikanten Abweichungen zwischen Patient und der Normalpopulation aufgefallen waren, wurde gezielt nach einer intragenische Deletion gesucht. Hierzu wurde von einem der Patienten zwei Maus-Hybridlinien generiert, die jeweils nur eines der beiden 10-er Homologe des Patienten enthalten. Doch auch hier waren die kodierenden Exons der 18 Gene aus beiden Hybridlinien durch PCR mit gleicher Effizienz und Größe amplifizierbar, so dass eine intragenische Deletionen mit großer Sicherheit bei allen Genen ausgeschlossen werden konnte. Des weiteren wurde nach SNPs in der transkribierten Sequenz der Kandidatengene gesucht, und die Expression beider Allele für 10 von 18 Kandidatengenen in Muskel-cDNA nachgewiesen. Kleine Veränderungen in nicht-kodierenden Bereichen, Introns, Promotor-Regionen, genomische Veränderungen oder de novo Insertionen sind mögliche pathogene Mechanismen, die im weiteren untersucht werden müssen. / In the first part of this work we characterised antibody-binding epitopes of human proteinase 3 (hPR3), the autoantigen in Wegeners granulomatosis (WG). WG is an autoimmune disorder characterized by chronic inflammation of the upper and lower respiratory tract, perivascular inflammation and glomerulonephritis. WG is associated with anti-neutrophil cytoplasmic antibodies (ANCA), which recognize conformational epitopes on the surface of hPR3 from azurophilic granules of neutrophil granulocytes. To determine, which epitopes are disease specific and pathogenetically relevant, we first identified a humanoid PR3 homolog which was used to map and distinguish the various ANCA-binding epitopes. We analysed the PR3 amino acid sequence of primates Pan troglodytes versus (chimpansee), Macacca mulatta (macaque) and Hylobates pileatus (gibbon) and compared the ANCA-binding pattern of these species to the human homolog. Amino acid differences and ANCA cross-reactivity correlated with the phylogenetic distance to the human homolog. We recognized the most useful PR3 variant was the gibbon equivalent (gibPR3) because it harboured a limited number of amino acid differences and showed an intermediate ANCA binding pattern with binding of some but not all monoclonal anti-hPR3 antibodies and WG patient sera. To determine the epitopes, we generated three PR3-chimera by reverting non-conserved PR3-loops to the respective human amino acids. ProPR3 was expressed in Flp-in 293 cells, purified from cell culture supernatant and activated by enterokinase. For epitope analysis an ELISA was developed, where PR3 was coupled via its C-terminal His6-tag to nickel-coated microtiter plates. The epitope of monoclonal anti-hPR3 antibody MCPR3-2 was mapped to a region defined by amino acids Arg60, Gln63A and Leu90 (chymotrypsinogen numbering), whereas Met35, Asn38A, Pro39B and Arg74 of the N-terminal PR3 domain contributed to the 12.8 epitope. The latter epitope was recognized by the majority of ANCA from Wegener patients tested and seems to be an ANCA-targeted region. The 12.8 epitope overlaps with the α1-PI binding site, too. Therefore antibody and inhibitor directly compete for binding to hPR3. Moreover we showed that antibody binding strongly depends on the concentration of this inhibitor. α1-PI-concentrations of 1 mg/ml allowed partial binding to PR3 and concentrations below shifted the binding towards the antibody. This finding indicates that a protease-inhibitor balance is critical because ANCA-binding to membrane bound PR3 on the surface of neutrophils would lead to activation and release of proteolytic enzymes to the environment and to an uncontrolled proteolytic activity. The second part of this studies were dedictated to the search for the genetic defect in a Swedish family suffering from autosomal dominant myofibrillar myopathy (MFM) in combination with arrhythmogenic right ventricular cardiomyopathy (ARVC7). In a comprehensive follow up study we reexamined the previous linkage data for MFM/ARVC7 by genome wide SNP analyses and confirmed the locus assignment using a high density single nucleotide polymorphism (SNP) marker panel from Affymetrix to 10q22.3. The critical interval was narrowed down to 4.1 Mbp between the two markers D10S1645 and D10S1786. Because no mutation was found in the coding exons of the 18 candidate genes for MFM/ARVC7 we tried to identify small genomic deletions and generated hybrid cell lines carrying only the affected or the normal chromosome 10 homolog. All sequence tagged sites and exons were present on both homologs excluding the possibility of intragenic and submicroscopic deletions. Furthermore, we identified SNPs within the transcribed sequences of 10 candidate genes and showed expression of both alleles in patient muscle cDNA. Subtle alterations in noncoding transcripts, introns, promoter regions or splicing enhancers, genomic inversions or de novo insertions are probably responsible for both disparate syndromes and have to be investigated.

Orientadora: Marcia Aparecida Silva Graminha / Banca: Jean Leandro dos Santos / Banca: Maria José Soares Mendes Giannini / Banca: Sergio de Albuquerque / Banca: André Luiz Pedrosa / Resumo: As leishmanioses são doenças causadas pelo protozoário parasito do gênero Leishmania e transmitidas pela picada do insetor vetor, o flebotomíneo. As leishmanioses apresentam diferentes manifestações clínicas, sendo elas leishmaniose cutânea, mucocutânea, cutânea difusa e visceral. Os fármacos atualmente disponíveis para o tratamento das leishmanioses apresentam diversos efeitos colaterais, além de problemas associados às vias de administração e surgimento de cepas resistentes. Os furoxanos e benzofuroxanos são compostos heterocíclicos contendo a função N-óxido com múltiplas atividades, incluindo anti-T. cruzi e anti-Leishmania. Neste trabalho, uma série de derivados de furoxano (compostos 3, 4a-b, 13a-b, e 14a-f) e benzofuroxano (7 e 8a-c) foram avaliados em ensaios in vitro frente as espécies L. (L.) amazonensis, L. (L.) mexicana e L. (L.) infantum. Os compostos foram também avaliados quanto à citotoxicidade em macrófagos murinos e quanto à sua capacidade de produção de óxido nítrico in vitro e em macrófagos infectados com o parasito. A atividade leishmanicida (EC50) dos derivados em estudo variou de 2,0 a 96,0 µM, enquanto que a citotoxicidade de 5,0 a 250,0 µM. A molécula doadora de óxido nítrico 14e revelou ser a mais promissora dentre os derivados analisados, exibindo ação pH-dependente. Adicionalmente, o derivado 14e mostrou ser capaz de inibir a enzima cisteíno protease de Leishmania, importante fator de virulência deste parasito. Estes ensaios mostraram que 14e inibe ... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Leishmaniases are diseases caused by the protozoan parasite of Leishmania genus and transmitted by the bite of insect vetor, phlebotomine. Leishmaniases present different clinical manifestations, including cutaneous, mucocutaneous, diffuse cutaneous and visceral leishmaniasis. The currently available drugs for leishmaniasis treatment show several side effects, besides problems associated with the administration routes and the emergence of resistant strains. Furoxan and benzofuroxan are heterocyclic compounds containing the N-oxide function showing several activities, including anti-T. cruzi and antiLeishmania. In this work, a series of furoxan (compounds 3, 4a-b, 13a-b, and 14a-f) and benzofuroxan (7 and 8a-c) derivatives were tested against the species L. (L.) amazonensis, L. (L.) mexicana e L. (L.) infantum. The compounds were also evaluated for cytotoxicity against murine macrophages and as to its ability to produce nitric oxide in vitro and in macrophages infected with the parasite. The antileishmanial activity (EC50) of the derivatives studied ranged from 2.0 to 96.0 μM, whereas the cytotoxicity of 5.0 to 250.0 μM. The nitric oxide donor molecule 14e revealed to be the most promising of the analyzed derivatives, exhibiting a pH-dependent action. Futhermore, the derivative 14e was shown to be capable of inhibiting the cysteine protease enzyme of Leishmania, an important virulence factor of this parasite. These assays showed that 14e inhibits the cysteine protease B 2.8 re... (Complete abstract click electronic access below) / Doutor

Le virus de la mosaïque jaune du navet (TYMV) est un excellent modèle pour la réplication des virus à ARN simple brin de polarité positive. Ce petit virus de plante code l’ensemble desprotéines nécessaires à sa réplication sous forme d’un précurseur polyprotéine (206K). Du NauC-terminus, celui-ci porte une activité méthyltransférase, protéase à cystéine (PRO),hélicase et ARN-polymérase ARN dépendante (POL). Comme tous les virus à ARN(+)connus, son complexe de réplication est étroitement lié à des membranes cellulaires. Dans lecas du TYMV, c’est l’enveloppe des chloroplastes qui est impliquée. Un des acteurs clés de laréplication est la polymérase qui permet la synthèse de nouveaux génomes. La régulation de son activité implique dans un premier temps son clivage de la 206K par PRO. Ainsi libérée,elle est recrutée aux chloroplastes par une interaction directe avec le domaine PRO du produit de clivage 140K, afin de former le complexe de réplication. Un second clivage par PRO contenu dans 140K, à la jonction PRO-hélicase, permet de poursuivre le cycle de réplication.Récemment, il a également été montré que l’activité POL était régulée par la voie ubiquitine-protéasome durant le cycle viral. Ubiquitinilée par la cellule hôte, elle est adressée au protéasome où elle sera dégradée. Cependant, PRO, grâce à sa seconde fonction ubiquitine hydrolase, est capable de la protéger de cette dégradation. Afin de caractériser d’un point de vue structural ce mécanisme de régulation de la réplication, nous avons cristallisé, à l’aide d’un contaminant, PRO et avons résolu sa structure. L’empilement cristallin est tel que le Cterminus d’un domaine PRO est inséré dans la crevasse catalytique du domaine PRO suivant,nous fournissant ainsi des informations structurales sur son activité endopeptidase. Dans un second temps, afin d’avoir des informations sur sa seconde activité, nous avons réalisé un complexe stable entre PRO et une molécule d’ubiquitine afin de le cristalliser et résoudre sa structure. Enfin, nous avons initié l’étude cristallographique de la polymérase. / Turnip Yellow Mosaic Virus is an excellent model for positive-stranded RNA virus replication. It’s a small plant virus whose replication machinery is encoded in the viralgenome as a single polyprotein (206K). From N- to C-terminus, this 206K harbors amethyltransferase, a cysteine proteinase (PRO), a helicase and an RNA-dependent RNApolymerase (POL). As in all RNA(+) viruses known, the replication complex is bound to cellmembranes. For TYMV, it ,is the chloroplast envelope that is implicated. A key component inthe replication process is the polymerase, that allows the synthesis of new genomes. The regulation of its activity involves initially its cleavage by PRO from the 206K. Once liberated,the polymerase is recruited to the chloroplasts through a direct interaction with the PROdomain, contained in 140K, in order to form the replication complex. A second cleavage of140K by PRO at the PRO-helicase junction allows to continue the replication cycle. Recently,it has also been shown that the POL activity was regulated by the ubiquitin-proteasomesystem during the viral multiplication cycle. Ubiquitinilated by the host cell, POL is addressed to the proteasome where it is degraded. However, PRO, due to its second function as an ubiquitin hydrolase, is able to protect POL from its degradation. In order to characterizethis mechanism of replication regulation with a structural point of view, we crystallized,assisted by contaminant, PRO and resolved its structure. In the crystal packing, the C-terminalof a PRO domain is inserted into the catalytic cleft of the next PRO domain, thus providing us structural informations on its endopeptidase activity. In a second step, in order to obtain information about its second activity, we made a stable complex between PRO and amolecule of ubiquitin in order to cristallise it. Finally, we initiated the crystallographic studyof POL.Keywords:

Introdução: As proteinases tem um papel importante no desenvolvimento, na destruição tecidual e na produção de muco causada pela DPOC. O inibidor de proteinase de origem vegetal Enterolobium contortisiliquum Tripsin Inhibitor (EcTI) inibe tanto as proteinases da classe serina quanto da classe cisteína. Objetivos: Avaliar os efeitos do tratamento com EcTI nas alterações pulmonares induzidas pela elastase em camundongos. Métodos: Camundongos C57Bl6 receberam elastase via intratraqueal (50 uL/animal, grupo ELA) ou salina (grupo SAL). Os camundongos foram tratados com EcTI (2mg/kg) nos dias 1, 15 e 21 após a instilação de elastase (grupo ELA-EcTI) ou salina (grupo SAL-EcTI). No dia 28 do protocolo, os animais foram anestesiados, a mecânica pulmonar foi medida e o óxido nítrico exalado coletado. Posteriormente, foi realizado o lavado broncoalveolar e os pulmões foram removidos para a preparação de lâminas de histoquímica e imunohistoquímica. Por meio de morfometria analisamos o número de células positivas para neutrófilos, TNF-alfa, MMP-9, MMP-12, TIMP-1, iNOS, eNOS assim como a fração de volume de 8-iso-PGF2alfa, fibras colágenas e elásticas, nos septos alveolares e nas vias aéreas. Também foram avaliados o número de células positivas para macrófagos nos septos alveolares e MUC5ac nas vias aéreas. Resultados: O inibidor de proteinase EcTI reduziu as alterações de mecânica pulmonar (Ers, Htis e Raw), destruição do septo alveolar (Lm) e o número de células no lavado broncoalveolar (células totais, macrófagos, neutrófilos, linfócitos e eosinógilos) induzidos pela elastase. Em relação a resposta inflamatória, o EcTI reduziu o número de neutrófilos e de células TNFalfa positivas no septo alveolar e nas vias aéreas além de reduzir o número de macrófagos no septo alveolar. Considerando o remodelamento de matriz extracelular, o inibidor de proteinase atenuou a fração de volume de fibras colágenas e o número de células MMP-9 e MMP-12 positivas nos septos alveolares e nas vias aéreas. Além disso, nas vias aéreas ocorreu uma atenuação da fração de volume de fibras elásticas, e nos septos alveolares uma atenuação da quantidade de células que expressam TIMP-1. Em relação a resposta de estresse oxidativo, o EcTI reduziu a fração de volume de isoprostano e o número de células iNOS e eNOS positivas tanto nos septos alveolares quanto nas vias aéreas. O EcTI também reduziu o número de células MUC5ac positivas nas vias aéreas. Conclusões: O tratamento como inibidor EcTI modulou a mecânica pulmonar e reduziu as alterações inflamatórias, de remodelamento e de estresse oxidativo induzidas pela elastase intratraqueal. Embora sejam necessários mais estudos para elucidar os mecanismos envolvidos neste processo, o inibidor de proteinase EcTI pode ser considerado como um potencial instrumento terapêutico para o tratamento da DPOC / Background: Proteinases play a key role on emphysema development, tissue destruction and mucus production. Enterolobium contortisiliquum Tripsin Inhibitor (EcTI) is a proteinase inhibitor from plant that neutralizes serine and cysteine proteinases. Aims: To evaluated the effects of the EcTI treatment in pulmonary alterations induced by elastase in mice. Methods: C57Bl6 mice received elastase intratracheally (50 uL/animal, ELA group) or saline (SAL group). Afterwards, mice were treated with EcTI (2 mg/kg) at days 1, 15 and 21 after elastase instillation (ELA-EcTI group). Control group received saline and EcTI using the same protocol (SAL-EcTI group). At day 28, mice were anesthetized, respiratory mechanics were collected, and exhaled nitric oxide were analyzed. Afterwards, broncoalveolar lavage fluid was obtained and lungs were removed to perform histochemistry and immunohistochemistry stains. By morphometry, the number of neutrophils, TNF-alfa, MMP-9, MMP-12, TIMP-1, iNOS, eNOS positive cells as well as the volume proportion of 8-iso-PGF2alfa, collagen and elastic fibers content in alveolar septum and airways walls were performed. In airways walls, we also analyzed the number of MUC-5 positive cells and the number of macrophages. Results: The proteinase inhibitor EcTI was able to reduce the pulmonary mechanical alterations (Ers, Htis and Raw), alveolar septum disruption (Lm) and the BAL cell count (total cells, macrophages, neutrophils, lymphocytes and eosinophils) induced by elastase. Regarding the inflammatory response, EcTI also reduced the number of neutrophils and TNFalfa positive cells in both alveolar septum and airway walls, and also reduced the number of macrophages in alveolar septum. Considering the extracellular matrix remodeling, the proteinase inhibitor attenuated the volume fraction of collagen fibers, MMP-9 and MMP-12 positive cells in both alveolar septum and airway walls. Besides, in airway there were attenuation in the volume fraction of elastic fibers, and in the alveolar septa a decrease of the amount of the cells expressing TIMP-1. Regarding the oxidative stress response, EcTI reduced the volume fraction of isoprostane and the number of iNOS and eNOS positive cells in both airways walls and alveolar septa, Finally, EcTI reduced the number of MUC5ac positive cells in airway walls. Conclusions: The treatment with EcTI modulated lung mechanics and reduced inflammatory, remodeling and oxidative stress alterations induced by elastase. Although more studies need to be performed to elucidate the mechanisms involved in this process, we may considerate EcTI as a potential therapeutic tool for COPD management

Introdução: As proteinases tem um papel importante no desenvolvimento, na destruição tecidual e na produção de muco causada pela DPOC. O inibidor de proteinase de origem vegetal Bauhinia bauhinioides Cruzipain Inhibitor (BbCI) inibe tanto as proteinases da classe serina quanto da classe cisteína. Objetivos: Deste modo consideramos relevante estudar os efeitos do tratamento com BbCI nas alterações pulmonares induzidas pela elastase em camundongos. Métodos: Camundongos C57Bl6 receberam elastase via intratraqueal (50 uL/animal, grupo ELA) ou salina (grupo SAL). Os camundongos foram tratados com BbCI (2mg/kg) nos dias 1, 15 e 21 após a instilação de elastase (grupo ELABC) ou salina (grupo SALBC). No dia 28 do protocolo, os animais foram anestesiados, a mecânica pulmonar foi medida e o óxido nítrico exalado coletado. Posteriormente, foi realizado o lavado broncoalveolar e os pulmões foram removidos para a preparação de lâminas de histoquímica e imunohistoquímica. Por meio de morfometria analisamos o número de células positivas para neutrófilos, TNF-alfa, MMP-9, MMP-12, TIMP-1, iNOS, eNOS assim como a fração de volume de 8-iso-PGF2alfa, fibras colágenas e elásticas, nos septos alveolares e nas vias aéreas. Também foram avaliados o número de células positivas para macrófagos nos septos alveolares e MUC5ac nas vias aéreas. Resultados: O inibidor de proteinase Tese de Doutorado Rafael Almeida-Reis BbCI reduziu as alterações de mecânica pulmonar (Ers, Htis e Raw), destruição do septo alveolar (Lm) e o número de células no lavado broncoalveolar (células totais, macrófagos e neutrófilos) induzidos pela elastase. Em relação a resposta inflamatória, o BbCI reduziu o número de neutrófilos e de células TNFalfa positivas no septo alveolar e nas vias aéreas além de reduzir o número de macrófagos no septo alveolar. Considerando o remodelamento de matriz extracelular, o inibidor de proteinase atenuou a fração de volume de fibras elásticas e colágenas e o número de células MMP- 9 e MMP-12 positivas nos septos alveolares e nas vias aéreas. Em relação a resposta de estresse oxidativo, o BbCI reduziu a fração de volume de isoprostano nas vias aéreas e o número de células iNOS positivas tanto nos septos alveolares quanto nas vias aéreas. O BbCI também reduziu o número de células MUC5ac positivas nas vias aéreas. Conclusões: O tratamento como inibidor BbCI modulou a mecânica pulmonar e reduziu as alterações inflamatórias, de remodelamento e de estresse oxidativo induzidas pela elastase intratraqueal. Embora sejam necessários mais estudos para elucidar os mecanismos envolvidos neste processo, o inibidor de proteinase BbCI pode ser considerado como um potencial instrumento terapêutico para o tratamento da DPOC / Background: Proteinases play a key role on emphysema development, tissue destruction and mucus production. Bauhinia bauhinioides Cruzipain Inhibitor (BbCI) is a proteinase inhibitor from plant that neutralizes serine and cysteine proteinases. The present study evaluated the effects of the BbCI treatment in pulmonary alterations induced by elastase in mice. Methods: C57Bl6 mice received elastase intratracheally (50 uL/animal, ELA group) or saline (SAL group). Afterwards, mice were treated with BbCI (2 mg/kg) at days 1, 15 and 21 after elastase instillation (ELABC group). Control group received saline and BbCI using the same protocol (SALBC group). At day 28, mice were anesthetized, respiratory mechanics were collected, and exhaled nitric oxide were analyzed. Afterwards, broncoalveolar lavage fluid was obtained and lungs were removed to perform histochemistry and immunohistochemistry stains. By morphometry, the number of neutrophils, TNFalfa, MMP-9, MMP-12, TIMP-1, iNOS, eNOS positive cells as well as the volume proportion of 8-iso-PGF2alfa, collagen and elastic fibers content in alveolar septum and airways walls were performed. In airways walls, we also analyzed the number of MUC-5 positive cells and the number of macrophages. Results: The proteinase inhibitor BbCI was able to reduce the pulmonary mechanical alterations (Ers, Htis and Raw), alveolar septum disruption (Lm) and the BAL cell count (total cells, macrophages and neutrophils) induced by elastase. Regarding the Tese de Doutorado Rafael Almeida-Reis inflammatory response, BbCI also reduced the number of neutrophils and TNFalfa positive cells in both alveolar septum and airway walls, and also reduced the number of macrophages in alveolar septum. Considering the extracellular matrix remodeling, the proteinase inhibitor attenuated the volume fraction of elastic and collagen fibers, MMP-9 and MMP-12 positive cells in both alveolar septum and airway walls. Regarding the oxidative stress response, BbCI reduced the volume fraction of isoprostane in airways and the number of iNOS positive cells in both airways walls and alveolar septum. Finally, BbCI reduced the number of MUC5ac positive cells in airway walls. Conclusions: The treatment with BbCI modulated lung mechanics and reduced inflammatory, remodeling and oxidative stress alterations induced by elastase. Although more studies need to be performed to elucidate the mechanisms involved in this process, but we may considerate BbCI as a potential therapeutic tool for COPD management

Introdução: As proteinases tem um papel importante no desenvolvimento, na destruição tecidual e na produção de muco causada pela DPOC. O inibidor de proteinase de origem vegetal Bauhinia bauhinioides Cruzipain Inhibitor (BbCI) inibe tanto as proteinases da classe serina quanto da classe cisteína. Objetivos: Deste modo consideramos relevante estudar os efeitos do tratamento com BbCI nas alterações pulmonares induzidas pela elastase em camundongos. Métodos: Camundongos C57Bl6 receberam elastase via intratraqueal (50 uL/animal, grupo ELA) ou salina (grupo SAL). Os camundongos foram tratados com BbCI (2mg/kg) nos dias 1, 15 e 21 após a instilação de elastase (grupo ELABC) ou salina (grupo SALBC). No dia 28 do protocolo, os animais foram anestesiados, a mecânica pulmonar foi medida e o óxido nítrico exalado coletado. Posteriormente, foi realizado o lavado broncoalveolar e os pulmões foram removidos para a preparação de lâminas de histoquímica e imunohistoquímica. Por meio de morfometria analisamos o número de células positivas para neutrófilos, TNF-alfa, MMP-9, MMP-12, TIMP-1, iNOS, eNOS assim como a fração de volume de 8-iso-PGF2alfa, fibras colágenas e elásticas, nos septos alveolares e nas vias aéreas. Também foram avaliados o número de células positivas para macrófagos nos septos alveolares e MUC5ac nas vias aéreas. Resultados: O inibidor de proteinase Tese de Doutorado Rafael Almeida-Reis BbCI reduziu as alterações de mecânica pulmonar (Ers, Htis e Raw), destruição do septo alveolar (Lm) e o número de células no lavado broncoalveolar (células totais, macrófagos e neutrófilos) induzidos pela elastase. Em relação a resposta inflamatória, o BbCI reduziu o número de neutrófilos e de células TNFalfa positivas no septo alveolar e nas vias aéreas além de reduzir o número de macrófagos no septo alveolar. Considerando o remodelamento de matriz extracelular, o inibidor de proteinase atenuou a fração de volume de fibras elásticas e colágenas e o número de células MMP- 9 e MMP-12 positivas nos septos alveolares e nas vias aéreas. Em relação a resposta de estresse oxidativo, o BbCI reduziu a fração de volume de isoprostano nas vias aéreas e o número de células iNOS positivas tanto nos septos alveolares quanto nas vias aéreas. O BbCI também reduziu o número de células MUC5ac positivas nas vias aéreas. Conclusões: O tratamento como inibidor BbCI modulou a mecânica pulmonar e reduziu as alterações inflamatórias, de remodelamento e de estresse oxidativo induzidas pela elastase intratraqueal. Embora sejam necessários mais estudos para elucidar os mecanismos envolvidos neste processo, o inibidor de proteinase BbCI pode ser considerado como um potencial instrumento terapêutico para o tratamento da DPOC / Background: Proteinases play a key role on emphysema development, tissue destruction and mucus production. Bauhinia bauhinioides Cruzipain Inhibitor (BbCI) is a proteinase inhibitor from plant that neutralizes serine and cysteine proteinases. The present study evaluated the effects of the BbCI treatment in pulmonary alterations induced by elastase in mice. Methods: C57Bl6 mice received elastase intratracheally (50 uL/animal, ELA group) or saline (SAL group). Afterwards, mice were treated with BbCI (2 mg/kg) at days 1, 15 and 21 after elastase instillation (ELABC group). Control group received saline and BbCI using the same protocol (SALBC group). At day 28, mice were anesthetized, respiratory mechanics were collected, and exhaled nitric oxide were analyzed. Afterwards, broncoalveolar lavage fluid was obtained and lungs were removed to perform histochemistry and immunohistochemistry stains. By morphometry, the number of neutrophils, TNFalfa, MMP-9, MMP-12, TIMP-1, iNOS, eNOS positive cells as well as the volume proportion of 8-iso-PGF2alfa, collagen and elastic fibers content in alveolar septum and airways walls were performed. In airways walls, we also analyzed the number of MUC-5 positive cells and the number of macrophages. Results: The proteinase inhibitor BbCI was able to reduce the pulmonary mechanical alterations (Ers, Htis and Raw), alveolar septum disruption (Lm) and the BAL cell count (total cells, macrophages and neutrophils) induced by elastase. Regarding the Tese de Doutorado Rafael Almeida-Reis inflammatory response, BbCI also reduced the number of neutrophils and TNFalfa positive cells in both alveolar septum and airway walls, and also reduced the number of macrophages in alveolar septum. Considering the extracellular matrix remodeling, the proteinase inhibitor attenuated the volume fraction of elastic and collagen fibers, MMP-9 and MMP-12 positive cells in both alveolar septum and airway walls. Regarding the oxidative stress response, BbCI reduced the volume fraction of isoprostane in airways and the number of iNOS positive cells in both airways walls and alveolar septum. Finally, BbCI reduced the number of MUC5ac positive cells in airway walls. Conclusions: The treatment with BbCI modulated lung mechanics and reduced inflammatory, remodeling and oxidative stress alterations induced by elastase. Although more studies need to be performed to elucidate the mechanisms involved in this process, but we may considerate BbCI as a potential therapeutic tool for COPD management

Introdução: As proteinases tem um papel importante no desenvolvimento, na destruição tecidual e na produção de muco causada pela DPOC. O inibidor de proteinase de origem vegetal Enterolobium contortisiliquum Tripsin Inhibitor (EcTI) inibe tanto as proteinases da classe serina quanto da classe cisteína. Objetivos: Avaliar os efeitos do tratamento com EcTI nas alterações pulmonares induzidas pela elastase em camundongos. Métodos: Camundongos C57Bl6 receberam elastase via intratraqueal (50 uL/animal, grupo ELA) ou salina (grupo SAL). Os camundongos foram tratados com EcTI (2mg/kg) nos dias 1, 15 e 21 após a instilação de elastase (grupo ELA-EcTI) ou salina (grupo SAL-EcTI). No dia 28 do protocolo, os animais foram anestesiados, a mecânica pulmonar foi medida e o óxido nítrico exalado coletado. Posteriormente, foi realizado o lavado broncoalveolar e os pulmões foram removidos para a preparação de lâminas de histoquímica e imunohistoquímica. Por meio de morfometria analisamos o número de células positivas para neutrófilos, TNF-alfa, MMP-9, MMP-12, TIMP-1, iNOS, eNOS assim como a fração de volume de 8-iso-PGF2alfa, fibras colágenas e elásticas, nos septos alveolares e nas vias aéreas. Também foram avaliados o número de células positivas para macrófagos nos septos alveolares e MUC5ac nas vias aéreas. Resultados: O inibidor de proteinase EcTI reduziu as alterações de mecânica pulmonar (Ers, Htis e Raw), destruição do septo alveolar (Lm) e o número de células no lavado broncoalveolar (células totais, macrófagos, neutrófilos, linfócitos e eosinógilos) induzidos pela elastase. Em relação a resposta inflamatória, o EcTI reduziu o número de neutrófilos e de células TNFalfa positivas no septo alveolar e nas vias aéreas além de reduzir o número de macrófagos no septo alveolar. Considerando o remodelamento de matriz extracelular, o inibidor de proteinase atenuou a fração de volume de fibras colágenas e o número de células MMP-9 e MMP-12 positivas nos septos alveolares e nas vias aéreas. Além disso, nas vias aéreas ocorreu uma atenuação da fração de volume de fibras elásticas, e nos septos alveolares uma atenuação da quantidade de células que expressam TIMP-1. Em relação a resposta de estresse oxidativo, o EcTI reduziu a fração de volume de isoprostano e o número de células iNOS e eNOS positivas tanto nos septos alveolares quanto nas vias aéreas. O EcTI também reduziu o número de células MUC5ac positivas nas vias aéreas. Conclusões: O tratamento como inibidor EcTI modulou a mecânica pulmonar e reduziu as alterações inflamatórias, de remodelamento e de estresse oxidativo induzidas pela elastase intratraqueal. Embora sejam necessários mais estudos para elucidar os mecanismos envolvidos neste processo, o inibidor de proteinase EcTI pode ser considerado como um potencial instrumento terapêutico para o tratamento da DPOC / Background: Proteinases play a key role on emphysema development, tissue destruction and mucus production. Enterolobium contortisiliquum Tripsin Inhibitor (EcTI) is a proteinase inhibitor from plant that neutralizes serine and cysteine proteinases. Aims: To evaluated the effects of the EcTI treatment in pulmonary alterations induced by elastase in mice. Methods: C57Bl6 mice received elastase intratracheally (50 uL/animal, ELA group) or saline (SAL group). Afterwards, mice were treated with EcTI (2 mg/kg) at days 1, 15 and 21 after elastase instillation (ELA-EcTI group). Control group received saline and EcTI using the same protocol (SAL-EcTI group). At day 28, mice were anesthetized, respiratory mechanics were collected, and exhaled nitric oxide were analyzed. Afterwards, broncoalveolar lavage fluid was obtained and lungs were removed to perform histochemistry and immunohistochemistry stains. By morphometry, the number of neutrophils, TNF-alfa, MMP-9, MMP-12, TIMP-1, iNOS, eNOS positive cells as well as the volume proportion of 8-iso-PGF2alfa, collagen and elastic fibers content in alveolar septum and airways walls were performed. In airways walls, we also analyzed the number of MUC-5 positive cells and the number of macrophages. Results: The proteinase inhibitor EcTI was able to reduce the pulmonary mechanical alterations (Ers, Htis and Raw), alveolar septum disruption (Lm) and the BAL cell count (total cells, macrophages, neutrophils, lymphocytes and eosinophils) induced by elastase. Regarding the inflammatory response, EcTI also reduced the number of neutrophils and TNFalfa positive cells in both alveolar septum and airway walls, and also reduced the number of macrophages in alveolar septum. Considering the extracellular matrix remodeling, the proteinase inhibitor attenuated the volume fraction of collagen fibers, MMP-9 and MMP-12 positive cells in both alveolar septum and airway walls. Besides, in airway there were attenuation in the volume fraction of elastic fibers, and in the alveolar septa a decrease of the amount of the cells expressing TIMP-1. Regarding the oxidative stress response, EcTI reduced the volume fraction of isoprostane and the number of iNOS and eNOS positive cells in both airways walls and alveolar septa, Finally, EcTI reduced the number of MUC5ac positive cells in airway walls. Conclusions: The treatment with EcTI modulated lung mechanics and reduced inflammatory, remodeling and oxidative stress alterations induced by elastase. Although more studies need to be performed to elucidate the mechanisms involved in this process, we may considerate EcTI as a potential therapeutic tool for COPD management

Ischaemic stroke has become one of the leading causes of death and disability in the world. Protease activated receptors (PARs, PAR-1 to PAR-4) belong to G protein coupled receptors that can be self-activated by tethered ligands (TL) revealed through proteolytic cleavage. Based on these TL, many activating peptides (APs) and antagonists have been synthesized to investigate PARs actions. / In the present study, the roles of PARs were examined in two models of ischaemic stroke. For the in vivo model, transient middle cerebral artery occlusion (tMCAO) was performed to establish cerebral ischaemia in rats. For the in vitro model, oxygen and glucose deprivation (OGD) was used to mimic an ischaemia insult in primary cultured rat embryonic cortical neurones. / Western blot studies showed that expressions of PAR-1 and PAR-2 were increased in the rat ischaemic brain cortex, whereas PAR-1 was reduced in the rat cortical neurones subjected to OGD. Pretreatments of PAR-1 AP (SFLLRN-NH₂) and PAR-2 AP (SLIGRL-NH₂) produced significant protection against ischaemia-induced damage. Pretreatment of PAR-3 AP (SFNGGP-NH₂) only improved ischaemic symptoms in in vivo but not in in vitro model. When treated after ischaemia, only PAR-1 AP produced significant reductions on ischaemia-induced damage. Protective actions of PAR-1 and PAR-2 APs were inhibited by PAR-1 antagonist (BMS-200261) and PAR-2 antagonist (ENMD-1068) respectively, but PAR-1 antagonist did not affect posttreatment effects of PAR-1 AP in in vitro model. Pre- and posttreatments of thrombin, and pretreatment of trypsin also protected ischaemia-induced damage in the two models. / PAR-1 AP produced marked increase in the activities of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and ratio of bcl-2/bax, but reduced contents of reactive oxygen species (ROS), nitric oxide (NO) and malondialdehyde (MDA) in both ipsilateral ischaemic brain cortices and in rat cortical neurones subjected to OGD. In the in vitro model, PAR-1 AP greatly decreased caspase-3 activity and TUNEL positive cells, while markedly increased mitochondrial membrane potential (MMP). All these protective actions were inhibited by its antagonist, which suggests it was mediated via activation of PAR-1. / In MCA isolated from normal and ischameic rats, PAR-2 AP and trypsin produced vasodilatation while PAR-3 AP elicited vasoconstriction. However, another PAR-3 AP had no effect in the two types of MCA. A high concentration of PAR-1 AP relaxed MCA isolated form ischaemic rats, and it was not inhibited by a PAR-1 antagonist. The vasodilator action of PAR-2 AP was inhibited by one of two PAR-2 antagonists tested. The vasodilator actions induced by PAR-1 and PAR-2 APs involved NO production since L-NAME was effective in inhibiting their actions. / In conclusion, PAR-1 AP was found to be the most efficacious in protecting the brain from ischaemia-induced damage when administered either before or after ischaemia insults. The protective actions were likely to be attributed to its anti-oxidant properties in the ischaemic brain that reduced apoptosis of brain cells. Therefore, PAR-1 was identified as a promising target for development of novel prophylactic and therapeutic treatments of ischaemic brain disease. / 缺血性腦中風已經成為全世界導致死亡和殘疾的最主要的疾病之一。蛋白酶激活受體（PARs, PAR-1 to PAR-4）屬於G蛋白偶聯受體並且可以通過蛋白水解生成系鎖配體（TL）從而作用於受體本身而激活信號通路。根據TL的序列已經合成了很多激活肽和拮抗劑，它們可以作為有價值的工具藥進行PAR的作用研究。 / 當前，PAR的作用在兩個缺血性腦中風模型中進行研究。體內模型是通過大鼠大腦中動脈阻塞手術而建立；體外模型是通過對大鼠胚胎大腦皮層神經元進行氧糖剝奪模擬缺血性損傷。 / 蛋白質印跡法的實驗表明PAR-1和PAR-2的表達在缺血側大腦皮層中有所增多，而PAR-1在氧糖剝奪的大鼠皮層神經元中表達卻有所降低。預處理PAR-1（SFLLRN-NH₂）和PAR-2（SLIGRL-NH₂）的激活肽顯著改善了缺血導致的損傷。預處理PAR-3激活肽（SFNGGP-NH₂）僅僅改善了體內缺血症狀，卻對體外缺血模型沒有效果。然而，當這些激活肽在缺血后給予的時候，只有PAR-1的激活肽顯著改善了缺血損傷。PAR-1的拮抗劑（BMS-200261）和PAR-2的拮抗劑（ENMD-1068）抑制了PAR-1和PAR-2激活肽的保護作用，但是體外實驗後處理PAR-1激活肽的保護作用卻未收影響。預處理及後處理凝血酶，預處理胰酶都在這兩個模型中顯示出保護缺血性損傷的作用。 / PAR-1激活肽在缺血同側大腦皮層以及經受氧糖剝奪的大鼠皮層神經元中，顯著提高了超氧化物歧化酶（SOD）、過氧化氫酶（CAT）、谷胱甘肽過氧化物酶（GSH-Px）的活力以及bcl-2/bax的比例，同時顯著降低了活性氧自由基（ROS）、一氧化氮（NO）以及丙二醛（MDA）的含量。在體外模型中，PAR-1激活肽還顯著降低了caspase-3的活力以及TUNEL陽性細胞的比例，同時顯著提高了線粒體膜電位（MMP）。所有這些作用都可以被拮抗劑抑制，說明PAR-1激活肽的保護作用是通過激活PAR-1介導的。 / 不管是從正常還是缺血的大鼠中分離出來的大腦中動脈，PAR-2激活肽和胰酶都可以使之舒張，PAR-3激活肽卻對其有收縮作用。然而，另外一種PAR-3激活肽卻未顯現出對血管活性的影響。高劑量的PAR-1激活肽只可以在分離于缺血大鼠的大腦中動脈中引起舒張，但此作用不能被其拮抗劑所抑制。PAR-2激活肽導致的血管舒張只可以被檢測的兩個拮抗劑中的其中一個所抑制。PAR-1和PAR-2激活肽引起的血管舒張與NO的產生有關，因為L-NAME可以有效抑制它們的作用。 / 總之，不管是預處理還是後處理的給藥方式，PAR-1的激活肽在保護大腦的缺血性損傷中都是最有效果的。保護作用可能可以歸因于其抗氧化以及抗凋亡的特性。所以，PAR-1是研究防治缺血性腦疾病的發展中富有希望的一個靶點。 / Zhen, Xia. / Thesis Ph.D. Chinese University of Hong Kong 2014. / Includes bibliographical references (leaves 194-206). / Abstracts also in Chinese. / Title from PDF title page (viewed on 11, October, 2016). / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only.

Since the catabolism of amino acids in cheese results in the formation of most volatile flavor compounds, a proper intracellular pool of amino acids must be established in order to produce a desirable flavor production in cheese. Generation of this pool of amino acids requires complex interactions among casein and its derivatives, proteolytic enzymes, and transport systems in the associated bacteria, including lactococci. In this project, we hypothesized that casein hydrolysis by the extracellular proteinases of Brevibacterium linens BL2 modulates the expression profile of proteolytic related genes in Lactococcus lactis spp. lactis IL1403. In order to monitor the global gene regulation patterns in L. lactis ssp. lactis IL1403, a high-throughput gene expression tool was needed to study the gene expression profiles on a genomic scale. In this project, we developed a novel oligonucleotide-based filter DNA array protocol for this purpose. The success of this oligonucleotide-based DNA array was dependent on technical innovations including polyI tailing, indirect high density biotin labeling, careful probe design, and integrated computational data analysis. The utility and validity of this protocol were demonstrated by profiling the expression of 375 metabolically related genes in L. lactis ssp. lactis IL1403 during heat, acid, and osmotic stresses. Subsequently the DNA macroarray was used to profile the gene expression changes of L. lactis spp. lactis IL1403 growing in a peptide-limited medium, in a casitone-based peptide-rich medium, and in a casein hydrolyte by B. linens BL2 proteolytic enzymes. L. lactis ssp. lactis IL1403 experienced nitrogen starvation even with an abundance of peptide resources because of lack of expression of peptide transporter genes. Conversely, a peptide pool generated by B. linens BL2 proteolytic activities was sufficient to sustain the growth of L. lactis ssp. lactis IL1403. The repression of the peptide transporter and other peptidase genes of L. lactis ssp. lactis IL1403 was relieved in this medium. Interestingly, the Opt system, a di-tripeptide transporter, was used as a primary peptide transporter, instead of the Opp system whose genes were not actively transcripted in IL1403. We also conducted additional experiments to further describe the protease in B. linens BL2 responsible for the peptide pool generation. This enzyme was secreted as a non-active zymogen and matured into the active protease. Both proteolysis and maturation processes were regulated. Collectively, this work demonstrated that a unique protease of B. linens BL2 generated a pool of pep tides transportable by L. lactis IL1403 and induced changes in gene expression in L. lactis IL1403. Consequently, this body of work demonstrated the hypothesis to be true.